New Delhi, July 26, 2022 : The product was launched at Le Méridien in New Delhi at an event attended by *Mr. Naor Gilon, Ambassador of Israel to India along with Eyal Copitt and Ido Mor from CardiacSense, and Pankaj Balwani from Xplore Lifestyle.
“Patients with irregular heart rhythms (Arrhythmia) in most cases don’t realize that they may be suffering from some of the life-threatening abnormal heart rhythms. With Atrial Fibrillation being the most serious of arrhythmias (irregular heartbeat) responsible for approximately 70% of ischemic strokes, CardiacSense is able to detect Atrial Fibrillation with over 99% accuracy. With CardiacSense, patients and their doctors will get alerts for life-threatening events. Also doctors can look through saved recordings on the Mobile App and cloud for all vital signs of patients, and will be able to assess what had really happened with the patient during a cardiac event. This 24/7 continuous monitoring capability gives very useful information in the hands of doctors who can diagnose and quickly start the right treatment for such patients, *said Mr. Pankaj Balwani, the founder & CEO of Xplore Lifestyle*.
“For over a decade now, Xplore Lifestyle has been at the forefront of various healthcare technologies introduced in the Indian market. We have an outstanding track record of bringing innovative MedTech devices derived from cutting edge technologies. In fact, Xplore Lifestyle is in the process of launching some more advanced life-saving medical devices forging collaborations with some of the best in the world. These technologies will completely transform the way hospitals and doctors deliver healthcare services to their patients today. Over the years, we have positioned ourselves as specialists in patient and health monitoring technologies and devices. With the launch of CardiacSense, we did not just wish to fill the market gap in terms of providing the most accurate Ambulatory Patient Monitoring Device in the world, we also wish to make people aware of the silent and life-threatening nature of some of the arrhythmias including Atrial Fibrillation and other chronic illnesses,” added Mr Balwani.
The device will be available in India from September 2022.
